PCT/GB97/03032 -

09/297703

Title:

Improvements in or Relating to Starch Content of Plants

Field of the Invention

This invention relates to novel nucleic acid sequences, vectors and host cells comprising the nucleic acid sequence(s), to polypeptides encoded thereby, and to a method of altering a host cell by introducing the nucleic acid sequence(s) of the invention.

Background to the Invention

Starch consists of two main polysaccharides, amylose and amylopectin. Amylose is a linear polymer containing α -1,4 linked glucose units, while amylopectin is a highly branched polymer consisting of a α -1,4 linked glucan backbone with α -1,6 linked glucan branches. In most plant storage reserves amylopectin consitutes about 75% of the starch content. Amylopectin is synthesized by the concerted action of soluble starch synthase and starch branching enzyme [α -1,4 glucan: α -1,4 glucan 6-glycosyltransferase, EC 2.4.1.18]. Starch branching enzyme (SBE) hydrolyses α -1,4 linkages and rejoins the cleaved glucan, via an α -1,6 linkage, to an acceptor chain to produce a branched structure. The physical properties of starch are strongly affected by the relative abundance of amylose and amylopectin, and SBE is therefore a crucial enzyme in determining both the quantity and quality of starches produced in plant systems.

Starches are commercially available from several plant sources including maize, potato and cassava. Each of these starches has unique physical characteristics and properties and a variety of possible industrial uses. In maize there are a number of naturally occurring mutants which have altered starch composition such as high amylopectin types ("waxy" starches) or high amylose starches but in potato and cassava no such mutants exist on a commercial basis as yet.

Genetic modification offers the possibility of obtaining new starches which may have novel and potentially useful characteristics. Most of the work to date has involved potato plants because they are amenable to genetic manipulation i.e. they can be transformed using Agrobacterium and regenerated easily from tissue culture. In addition many of the genes involved in starch biosynthesis have been cloned from potato and thus are available as targets for genetic manipulation, for example, by antisense inhibition of expression or sense suppression.

Cassava (Manihot esculenta L. Crantz) is an important crop in the tropics, where its starch-filled roots are used both as a food source and increasingly as a source of starch. Cassava is a high yielding perennial crop that can grow on poor soils and is also tolerant of drought. Cassava starch being a root-derived starch has properties similar but not identical to potato starch and is composed of 20-25% amylose and 75-80% amylopectin (Rickard et al., 1991. Trop. Sci. 31, 189-207). Some of the genes involved in starch biosynthesis have been cloned from cassava, including starch branching enzyme I (SBE I) (Salehuzzaman et al., 1994 Plant Science 98, 53-62), and granule bound starch synthase I (GBSS I) (Salehuzzaman et al., 1993 Plant Molecular Biology 23, 947-962) and some work has been done on their expression patterns although only in in vitro grown plants (Salehuzzaman et al., 1994 Plant Science 98, 53-62).

In most plants studied to date e.g. maize (Boyer & Preiss, 1978 Biochem. Biophys. Res. Comm. 80, 169-175), rice (Smyth. 1988 Plant Sci. 57, 1-8) and pea (Smith, Planta 175, 270-279). two forms of SBE have been identified, each encoded by a separate gene. A recent review by Burton et al., (1995 The Plant Journal 7, 3-15) has demonstrated that the two forms of SBE constitute distinct classes of the enzyme such that, in general, enzymes of the same class from different plants may exhibit greater similarity than enzymes of different classes from the same plant. In their review, Burton et al. termed the two respective enzyme families class "A" and class "B", and the reader is referred thereto (and to the references cited therein) for a detailed discussion of the distinctions between the two classes. One general distinction of note would appear to be the presence, in class A SBE molecules, of a flexible N-terminal domain, which is not found in class B molecules. The distinctions noted by Burton et al. are relied on herein to define class A and class B SBE

molecules, which terms are to be interpreted accordingly.

Many organisations have interests in obtaining modified Cassava starches by means of genetic modification. This is impossible to achieve however, unless the plant is amenable to transformation and regeneration, and the starch biosynthesis genes which are to be targeted for modification must be cloned. The production of transgenic cassava plants has only recently been demonstrated (Taylor et al., 1996 Nature Biotechnology 14, 726-730; Schöpke et al., 1996 Nature Biotechnology 14, 731-735; and Li et al., 1996 Nature Biotechnology 14, 736-740). The present invention concerns the identification, cloning and sequencing of a starch biosynthetic gene from Cassava, suitable as a target for genetic manipulation.

Summary of the Invention

In a first aspect the invention provides a nucleic acid sequence encoding a polypeptide having starch branching enzyme (SBE) activity, the polypeptide comprising an effective portion of the amino acid sequences shown in Figure 4 or Figure 13. The nucleic acid is conveniently in substantial isolation, especially in isolation from other naturally associated nucleic acid sequences.

An "effective portion" of the amino acid sequences may be defined as a portion which retains sufficient SBE activity when expressed in *E. coli* KV832 to complement the branching enzyme mutation therein. The amino acid sequences shown in Figures 4 and 13 include the N terminal transit peptide, which comprises about the first 50 amino acid residues. As those skilled in the art will be well aware, such a transit peptide is not essential for SBE activity. Thus the mature polypeptide, lacking a transit peptide, may be considered as one example of an effective portion of the amino acid sequence shown in Figure 4 or Figure 13.

Other effective portions may be obtained by effecting minor deletions in the amino acid sequence, whilst substantially preserving SBE activity. Comparison with known class A SBE sequences, with the benefit of the disclosure herein, will enable those skilled in the

art to identify regions of the polypeptide which are less well conserved and so amenable to minor deletion, or amino acid substitution (particularly, conservative amino acid substitution) whilst substantially preserving SBE activity. Such less well-conserved regions are generally found in the N terminal amino acid residues (up to the triple proline "elbow" at residues 138-140 in Figure 4 and up to the proline elbow at residues 143-145 in Figure 13) and in the last 50 residues or so of the C terminal, and in particular in the acidic tail of the C terminal.

Conveniently the nucleic acid sequence is obtainable from cassava, preferably obtained therefrom, and typically encodes a polypeptide obtainable from cassava. In a particular embodiment, the encoded polypeptide may have the amino acid sequence NSKH at about position 697 (in relation to Figure 4), which sequence appears peculiar to an isoform of the SBE class A enzyme of cassava, other class A SBE enzymes having the conserved sequence DA D/E Y (Burton *et al.*, 1995 cited above).

In a particular aspect of the invention there is provided a nucleic acid comprising a portion of nucleotides 21 to 2531 of the nucleic acid sequence shown in Figure 4, or a functionally equivalent nucleic acid sequence. Such functionally equivalent nucleic acid sequences include, but are not limited to, those sequences which encode substantially the same amino acid sequence but which differ in nucleotide sequence from that shown in Figure 4 by virtue of the degeneracy of the genetic code. For example, a nucleic acid sequence may be altered (e.g. "codon optimised") for expression in a host other than cassava, such that the nucleotide sequence differs substantially whilst the amino acid sequence of the encoded polypeptide is unchanged. Other functionally equivalent nucleic acid sequences are those which will hybridise under stringent hybridisation conditions (e.g. as described by Sambrook et al., Molecular Cloning. A Laboratory Manual, CSH, i.e. washing with 0.1xSSC, 0.5% SDS at 68°C) with the sequence shown in Figure 4. Figure 10 shows a functionally equivalent sequence designated "125 + 94", which includes a region corresponding to the 3' coding portion of the sequence in Figure 4. Figure 13 shows a functionally equivalent sequence which comprises a second complete SBE coding sequence (the SBE-derived sequence is from nucleotides 35 to 2760, of which the coding sequence is nucleotides 131-2677, the rest of the sequence in the figure is vector-derived).

Functionally equivalent DNA sequences will preferably comprise at least 200-300bp, more preferably 300-600bp, and will exhibit at least 88% identity (more preferably at least 90%, and most preferably at least 95% identity) with the corresponding region of the DNA sequence shown in figures 4 or 10. Those skilled in the art will readily be able to conduct a sequence alignment between the putative functionally equivalent sequence and those detailed in Figures 4 or 10 - the identity of the two sequences is to be compared in those regions which are aligned by standard computer software, which aligns corresponding regions of the sequences.

In particular embodiments the nucleic acid sequence may alternatively comprise a 5' and/or a 3' untranslated region ("UTR"), examples of which are shown in Figures 2 and 4. Figure 9 includes a 3' UTR, as nucleotides 688-1044 and Figure 10 includes 3' UTR as nucleotides 1507-1900 (which nucleotides correspond to the first base after the "stop" codon to the base immediately preceding the poly (A) tail). Any one of the sequences defined above, or a functional equivalent thereof (as defined by hybridisation properties, as set out in the preceding paragraph), could be useful in sense or anti-sense inhibition of corresponding genes, as will be apparent to those skilled in the art. It will also be apparent to those skilled in the art that such regions may be modified so as to optimise expression in a particular type of host cell and that the 5' and/or 3' UTRs could be used in isolation, or in combination with a coding portion of the sequence of the invention. Similarly, a coding portion could be used without a 5' or a 3' UTR if desired.

In a further aspect, the invention provides a replicable nucleic acid construct comprising any one of the nucleic acid sequences defined above. The construct will typically comprise a selectable marker and may allow for expression of the nucleic acid sequence of the invention. Conveniently the vector will comprise a promoter (especially a promoter sequence operable in a plant and/or a promoter operable in a bacterial cell) and one or more regulatory signals known to those skilled in the art.

In another aspect the invention provides a polypeptide having SBE activity, the polypeptide comprising an effective portion of the amino acid sequence shown in Figure 4 or Figure 13. The polypeptide is conveniently one obtainable from cassava, although it may be

derived using recombinant DNA techniques. The polypeptide is preferably in substantial isolation from other polypeptides of plant origin, and more preferably in substantial isolation from any other polypeptides. The polypeptide may have amino acid residues NSKH at about position 697 (in the sequence shown in Figure 4), instead of the sequence DA D/E Y found in other SBE class A polypeptides. The polypeptide may be used in a method of modifying starch *in vitro*, the method comprising treating starch under suitable conditions (of temperature, pH etc.) with an effective amount of the polypeptide.

Those skilled in the art will appreciate that the disclosure of the present specification can be utilised in a number of ways. In particular, the characteristics of a host cell may be altered by recombinant DNA techniques. Thus, in a further aspect, there is provided a method by which a host cell may be altered by introduction of a nucleic acid sequence comprising at least 200bp and exhibiting at least 88% sequence identity (more preferably at least 90%, and most preferably at least 95% identity) with the corresponding region of the DNA sequence shown in Figures 4, 9, 10 or 13, operably linked in the sense or (preferably) in the anti-sense orientation to a suitable promoter active in the host cell, and causing transcription of the introduced nucleic acid sequence, said transcript and/or the translation product thereof being sufficient to interfere with the expression of a homologous gene naturally present in said host cell, which homologous gene encodes a polypeptide having SBE activity. The altered host cell is typically a plant cell, such as a cell of a cassava, banana, potato, sweet potato, tomato, pea, wheat, barley, oat, maize, or rice plant.

Desirably the method further comprises the introduction of one or more nucleic acid sequences which are effective in interfering with the expression of other homologous gene or genes naturally present in the host cell. Such other genes whose expression is inhibited may be involved in starch biosynthesis (e.g. an SBE I gene), or may be unrelated to SBE II.

Those skilled in the art will be aware that both anti-sense inhibition, and "sense suppression" of expression of genes, especially plant genes, has been demonstrated (e.g. Matzke & Matzke 1995 Plant Physiol. 107, 679-685).

It is believed that antisense methods are mainly operable by the production of antisense mRNA which hybridises to the sense mRNA, preventing its translation into functional polypeptide, possibly by causing the hybrid RNA to be degraded (e.g. Sheehy et al., 1988 PNAS 85, 8805-8809; Van der Krol et al., Mol. Gen. Genet. 220, 204-212). Sense suppression also requires homology between the introduced sequence and the target gene, but the exact mechanism is unclear. It is apparent however that, in relation to both antisense and sense suppression, neither a full length nucleotide sequence, nor a "native" sequence is essential. Preferably the nucleic acid sequence used in the method will comprise at least 200-300bp, more preferably at least 300-600bp, of the full length sequence, but by simple trial and error other fragments (smaller or larger) may be found which are functional in altering the characteristics of the plant. It is also known that untranslated portions of sequence can suffice to inhibit expression of the homologous gene - coding portions may be present within the introduced sequence, but they do not appear to be essential under all circumstances.

The inventors have discovered that there are at least two class A SBE genes in cassava. A fragment of a second gene has been isolated, which fragment directs the expression of the C terminal 481 amino acids of cassava class A SBE (see Figure 10) and comprises a 3' untranslated region. Subsequently, a complete clone of the second gene was also recovered (see Figure 12). The coding portions of the two genes show some slight differences, and the second SBE gene may be considered as functionally equivalent to the corresponding portion of the nucleotide sequence shown in Figure 4. However, the 3' untranslated regions of the two genes show marked differences. Thus the method of altering a host cell may comprise the use of a sufficient portion of either gene so as to inhibit the expression of the naturally occurring homologous gene. Conveniently, a portion of nucleotide sequence is employed which is conserved between both genes. Alternatively, sufficient portions of both genes may be employed, typically using a single construct to direct the transcription of both introduced sequences.

In addition, as explained above, it may be desired to cause inhibition of expression of the class B SBE (i.e. SBE I) in the same host cell. A number of class B SBE gene sequences are known, including portions of the cassava class B SBE (Salehuzzaman et al., 1994)

Plant Science 98, 53-62) and any one of these may prove suitable. Preferably the sequence used is that which derives from the host cell sought to be altered (e.g. when altering the characteristics of a cassava plant cell, it is generally preferred to use sense or anti-sense sequences corresponding exactly to at least portions of the cassava gene whose expression is sought to be inhibited).

In a further aspect the invention provides an altered host cell, into which has been introduced a nucleic acid sequence comprising at least 200bp and exhibiting at least 88% sequence identity (more preferably at least 90%, and most preferably at least 95% identity) with the corresponding region of the DNA sequence shown in Figures 4, 9, 10 or 13, operably linked in the sense or anti-sense orientation to a suitable promoter, said host cell comprising a natural gene sharing sequence homology with the introduced sequence.

The host cell may be a micro-organism (such as a bacterial, fungal or yeast cell) or a plant cell. Conveniently the host cell altered by the method is a cell of a cassava plant, or another plant with starch storage reserves, such as banana, potato, sweet potato, tomato, pea, wheat, barley, oat, maize, or rice plant. Typically the sequence will be introduced in a nucleic acid construct, by way of transformation, transduction, micro-injection or other method known to those skilled in the art. The invention also provides for a plant into which has been introduced a nucleic acid sequence of the invention, or the progeny of such a plant.

The altered plant cell will preferably be grown into an altered plant, using techniques of plant growth and cultivation well-known to those skilled in the art of re-generating plantlets from plant cells.

The invention also provides a method of obtaining starch from an altered plant, the plant being obtained by the method defined above. Starch may be extracted from the plant by any of the known techniques (e.g. milling). The invention further provides starch obtainable from a plant altered by the method defined above, the starch having altered properties compared to starch extracted from an equivalent but unaltered plant. Conveniently the altered starch is obtained from an altered plant selected from the group

Pe Pe

consisting of cassava, potato, pea, tomato, maize, wheat, barley, oat, sweet potato and rice. Typically the altered starch will have increased amylose content.

9

The invention will now be further described by way of illustrative examples and with reference to the accompanying drawings, in which:-

Figure 1 is a schematic illustration of the cloning strategy for cassava SBE II. The top line represents the size of a full length clone with distances in kilobases (kb) and arrows representing oligonucleotides (rightward pointing arrows are sense strand, leftward are on opposite strand). The long thick arrow is the open reading frame with start and stop codons shown. Below this are shown the 3' RACE, 5' RACE and PCR clones identified either by the plasmid name (shown in brackets above the line) or the clone number (shown to the left of the clone) for the 5' RACE only. Also shown (by an x) in the 5' RACE clones are positions of small deletions or introns.

Figure 2 shows the DNA sequence and predicted ORF of csbe2con.seq. This sequence is a consensus of 3' RACE pSJ94 and 5' RACE clones 27/9,11 and 28. The first 64 base pairs are derived from the RoRidT17 adaptor primer/dT tail followed by the SBE sequence. The one long open reading frame is shown in one letter code below the double strand DNA sequence. Also shown is the upstream ORF (MQL...LPW).

Figure 3 shows an alignment of the 5' region of cassava SBE II csbe2con and pSJ99 (clones 20 and 35) DNA sequences. Differences from the consensus sequence are shaded.

Figure 4 shows the DNA sequence and predicted ORF of full length cassava SBE II tuber cDNA in pSJ107. The sequence shown is from the CSBE214 to the CSBE218 oligonucleotide. The DNA sequence is sequence ID No. 28 in the attached sequence listing; the amino acid sequence is Seq ID No. 29.

Figure 5 shows an alignment of 3' region of cassava SBE II pSJ116 and 125+94 DNA sequences. The top line is the 125 + 94 sequence and the bottom SJ116 sequence. Identical nucleotides are indicated by the same letter in the middle line, differences are

indicated by a gap, and dashed lines indicate gaps introduced to optimise alignment.

Figure 6 shows an alignment of carboxy terminal region of pSJ116 and 125+94 protein sequences. The top sequence is from 125+94 and the bottom from pSJ116. Identical amino acid residues are shown with the same letter, conserved changes with a colon and neutral changes with a period.

Figure 7 shows a phylogenetic tree of starch branching enzyme proteins. The length of each pair of branches represents the distance between sequence pairs. The scale beneath the tree measures the distance between sequences (units indicate the number of substitution events). Dotted lines indicate a negative branch length because of averaging the tree. Zmcon12.pro is maize SBE II, psstb1.pro is pea SBE I (Bhattacharyya et al 1990 Cell 60, 115-121) and atsbe2-1 & 2-2.pro are two SBE II proteins from Arabidopsis thalania (Fisher et al 1996 Plant Mol. Biol. 30, 97-108). SJ107.pro is representative of a cassava SBE II sequence, and potsbe2.pro is a potato SBE II sequence known to the inventors.

Figure 8 is an alignment of SBE II proteins. Protein sequences are indicated in one letter code. The top line represents the consensus sequence, below which is shown the consensus ruler and the individual SBE II sequences. Residues matching the consensus are shaded. Dashes represent gaps introduced to optimise alignment. Sequence identities are shown at the right of the figure and are as Figure 7, except that SJ107 pro is cassava SBE II.

Figure 9 shows the DNA sequence and predicted ORF of a cassava SBE II cDNA isolated by 3' RACE (plasmid pSJ 101).

Figure 10 shows the consensus DNA sequence and predicted ORF of a second cassava SBE II cDNA isolated by 3' and 5' RACE (sequence designated 125+94 is from plasmid pSJ125 and pSJ94, spliced at the CSBE217 oligo sequence).

Figure 11 is a schematic diagram of the plant transformation vector pSJ64. The black line represents the DNA sequence. The hashed line represents the bacterial plasmid backbone

(containing the origin of replication and bacterial selection marker) and is not shown in full. The filled triangles represent the T-DNA borders (RB = right border, LB = left border). Relevant restriction enzyme sites are shown above the black line with the approximate distances (in kiloobases) betwen sites marked by an asterisk shown underneath. The thinnest arrows represent polyadenylation signals (pAnos = nopaline synthase, pAg7 = Agrobacterium gene 7), the intermediate arrows represent protein coding regions (SBE II = cassava SBE II, HYG = hygromycin resistance gene) and the thick arrows represent promoter regions (P-2x35S = double CaMV 35S promoter, P-nos = nopaline synthase promoter).

11

Figure 12 is a schematic illustration of the cloning strategy used to isolate a second cassava SBE II gene. The top line represents the size of a full length clone with distances in kilobases (kb) and arrows representing oligonucleotides (rightward pointing arrows are sense strand, leftward are on opposite strand). The long thick arrow is the open reading frame with start and stop codons shown. Below this are shown the 3' RACE, 5' RACE and PCR clones identified either by the plasmid name (shown in brackets above the line) or the clone number (shown to the right of the clone).

Figure 13 shows the DNA sequence and predicted ORF of a second full length cassava SBE II tuber cDNA in pSJ146. Nucleotides 35-2760 are SBE II sequence and the remainder are from the pT7Blue vector. The DNA sequence of Figure 13 is Seq ID No. 30, and the amino acid sequence is Seq ID No. 31, in the attached sequence listing.

Example 1

This example relates to the isolation and cloning of SBE II sequences from cassava.

Recombinant DNA manipulations

Standard procedures were performed essentially according to Sambrook *et al.* (1989 Molecular cloning A laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). DNA sequencing was performed on an ABI automated DNA sequencer and sequences manipulated using DNASTAR software for the Macintosh.

Rapid Amplification of cDNA ends (RACE) and PCR conditions

5' and 3' RACE were performed essentially according to Frohman et al., (1988 Proc. Natl. Acad. Sci. USA 85, 8998-9002) but with the following modifications.

For 3' RACE, 5 μ g of total RNA was reverse transcribed using 5 pmol of the RACE adaptor RoRidT17 as primer and Stratascript RNAse H- reverse transcriptase (50 U) in a 50 μ l reaction according to the manufacturer's instructions (Stratagene). The reaction was incubated for 1 hour at 37°C and then diluted to 200 μ l with TE (10 mM Tris HCl, 1 mM EDTA) pH 8 and stored at 4°C. 2.5 μ l of this cDNA was used in a 25 μ l PCR reaction with 12.5 pmol of SBE A and Ro primers for 30 cycles of 94°C 45 sec, 50°C 25 sec, 72°C 1 min 30 sec. A second round of PCR (25 cycles) was performed using 1 μ l of this reaction as template in a 50 μ l reaction under the same conditions. Amplified products were separated by agarose gel electrophoresis and cloned into the pT7Blue vector (Invitrogen).

For the first round of 5' RACE, 5 μ g of total leaf RNA was reverse transcribed as described above using 10 pmol of the SBE II gene specific primer CSBE22. This primer was removed from the reaction by diluting to 500 μ l with TE and centrifuging twice through a centricon 100 microconcentrator. The concentrated cDNA was then dA-tailed with 9U of terminal deoxynucleotide transferase and 50 μ M dATP in a 20 μ l reaction in buffer supplied by the manufacturer (BRL). The reaction was incubated for 10 min at 37°C and 5 min at 65°C and then diluted to 200 μ l with TE pH 8. PCR was performed in a 50 μ l volume using 5 μ l of tailed cDNA, 2.5 pmol of RoRidT17 and 25 pmol of Ro and CSBE24 primers for 30 cycles of 94°C 45 sec, 55°C 25 sec, 72°C 3 min. Amplified products were separated on a 1% TAE agarose gel, cut out, 200 μ l of TE was added and melted at 99°C for 10 min. Five μ l of this was re-amplified in a 50 μ l volume using CSBE25 and Ri as primers and 25 cycles of 94°C 45 sec, 55°C 25 sec, 72°C 1 min 30 sec. Amplified fragments were separated on a 1% TAE agarose gel, purified on DEAE paper and cloned into pT7Blue.

The second round of 5' RACE was performed using CSBE28 and 29 primers in the first and second round PCR reactions respectively using a new A-tailed cDNA library primed

with CSBE27.

A third round of 5' RACE was performed on the same CSBE27 primed cDNA.

Repeat 3' RACE and PCR Cloning

The 3' RACE library (RoRidT17 primed leaf RNA) was used as a template. The first PCR reaction was diluted 1:20 and 1 μ l was used in a 50 μ l PCR reaction with SBE A and Ri primers and the products were cloned into pT7Blue. The cloned PCR products were screened for the presence or absence of the CSBE23 oligo by colony PCR.

A full length cDNA of cassava SBE II was isolated by PCR from leaf or root cDNA (RoRidT17 primed) using primers CSBE214 and CSBE218 from 2.5 μ l of cDNA in a 25 μ l reaction and 30 cycles of 94°C 45 sec, 55°C 25 sec, 72°C 2 min.

Complementation of E. coli mutant KV832

SBE II containing plasmids were transformed into the branching enzyme deficient mutant E.~coli~KV832 (Keil et al., 1987 Mol. Gen. Genet. 207, 294-301) and cells grown on solid PYG media (0.85 % KH₂PO₄, 1.1 % K₂HPO₄, 0.6 % yeast extract) containing 1.0 % glucose. To test for complementation, a loop of cells was scraped off and resuspended in 150 μ L water to which was added 15 μ L of Lugol's solution (2 g KI and 1 g I₂ per 300 ml water).


RNA isolation

RNA was isolated from cassava plants by the method of Logemann (1987 Anal. Biochem. 163, 21-26). Leaf RNA was isolated from 0.5 gm of in vitro grown plant tissue. The total yield was 300 μ g. Three month old roots (88 gm) were used for isolation of root RNA).

SBE II specific oligonucleotides

SBE A ATGGACAAGGATATGTATGA (Seq ID No. 1)

CSBE21 GGTTTCATGACTTCTGAGCA (Seq ID No. 2)



TGGTTGTTCCCTGGAATTAC

TGCAAGGACCGTGACATCAA

RESULTS

CSBE217

CSBE218

Cloning of a SBE II gene from cassava leaf

The strategy for cloning a full length cDNA of starch branching enzyme II of cassava is shown in Figure 1. A comparison of several SBE II (class A) SBE DNA sequences identified a 23 bp region which appears to be completely conserved among most genes (data not shown) and is positioned about one kilobase upstream from the 3' end of the gene. An oligonucleotide primer (designated SBE A) was made to this sequence and used to isolate a partial cDNA clone by 3' RACE PCR from first strand leaf cDNA as illustrated in Figure 1. An approximately 1100 bp band was amplified, cloned into pT7Blue vector and sequenced. This clone was designated pSJ94 and contained a 1120 bp insert starting with the SBE A oligo and ending with a polyA tail. There was a predicted open reading frame of 235 amino acids which was highly homologous (79% identical) to a potato SBE II also isolated by the inventors (data not shown) suggesting that this clone represented a class A (SBE II) gene.

(Seq ID No. 18)

(Seq ID No. 19)

To obtain the sequence of a full length clone nested primers were made complementary to the 5' end of this sequence and used in 5' RACE PCR to isolate clones from the 5' region of the gene. A total of three rounds of 5' RACE was needed to determine the sequence of the complete gene (i.e. one that has a predicted long ORF preceded by stop codons). It should be noted that during this cloning process several clones (# 23, 9, 16) were obtained that had small deletions and in one case (clone 23) there was also a small (120 bp) intron present. These occurrences are not uncommon and probably arise through errors in the PCR process and/or reverse transcription of incompletely processed RNA (heterogeneous nuclear RNA).

The overlapping cDNA fragments could be assembled into a contiguous 3 kb sequence (designated csbe2con.seq) which contained one long predicted ORF as shown in Figure 2. Several clones in the last round of 5' RACE were obtained which included sequence of the untranslated leader (UTL). All of these clones had an ORF (42 amino acids) 46 bp upstream and out of frame with that of the long ORF.

There is more than one SBE II gene in cassava

In order to determine if the assembled sequence represented that of a single gene, attempts were made to recover by PCR a full length SBE II gene using primers CSBE214 and CSBE23 at the 5' and 3' ends of the csbe2con sequence respectively. All attempts were unsuccessful using either leaf or root cDNA as template. The PCR was therefore repeated with either the 5'- or 3'- most primer and complementary primers along the length of the SBE II gene to determine the size of the largest fragment that could be amplified. With the CSBE214 primer, fragments could be amplified using primers 210, 28, 27 and 22 in order of increasing distance, the latter primer pair amplifying a 2.2 kb band. With the 3' primer CSBE23, only primer pairs with 21 and 26 gave amplification products, the latter being about 1200 bp. These results suggest that the original 3' RACE clone (pSJ94) is derived from a different SBE II gene than the rest of the 5' RACE clones even though the two largest PCR fragments (214+22 and 26+23) overlap by 750 bp and share several primer sites. It is likely that the sequence of the two genes starts to diverge around the CSBE22 primer site such that the 3' end of the corresponding gene does not contain the 23 primer and is not therefore able to amplify a cDNA when used with the 214 primer.

To confirm this, the sequence of the longest 5' PCR fragment (214+22) from two clones (#20 designated pSJ99, & #35) was determined and compared to the consensus sequence csbe2con as shown in Figure 3. The first 2000 bases are nearly identical (the single base changes might well be PCR errors), however the consensus sequence is significantly different after this. This region corresponds to the original 3' RACE fragment pSJ94 (SBE A + Ri adaptor) and provided evidence that there may be more than one SBE II gene in cassava.

The 3' end corresponding to pSJ99 was therefore cloned as follows: 3' RACE PCR was performed on leaf cDNA using the SBE A oligo as the gene specific primer so that all SBE II genes would be amplified. The cloned DNA fragments were then screened for the presence or absence of the CSBE23 primer by PCR. Two out of 15 clones were positive with the SBE A + Ri primer pair but negative with SBE A + CSBE23 primers. The sequence of these two clones (designated pSJ101, as shown in Figure 9) demonstrated that they were indeed from an SBE II gene and that they were different from pSJ94. However the overlapping region of pSJ101 (the 3' clone) and pSJ99 (the 5' clone) was identical suggesting that they were derived from the same gene.

To confirm this a primer (CSBE218) was made to a region in the 3' UTR (untranslated region) of pSJ101 and used in combination with CSBE214 primer to recover by PCR a full length cDNA from both leaf and root cDNA. These clones were sequenced and designated pSJ106 & pSJ107 respectively. The sequence and predicted ORF of pSJ107 is shown in Figure 4. The long ORF in plasmid pSJ106 was found to be interrupted by a stop codon (presumably introduced in the PCR process) approximately 1 kb from the 3' end of the gene, therefore another cDNA clone (designated pSJ116) was amplified in a separate reaction, cloned and sequenced. This clone had an intact ORF (data not shown). There were only a few differences in these two sequences (in the transit peptide aa 27-41: YRRTSSCLSFNFKEA to DRRTSSCLSFIFKKAA and L831 in pSJ107 to V in pSJ116 respectively).

An additional 740bp of sequence of the gene corresponding to the pSJ94 clone was isolated by 5' RACE using the primers CSBE216 and 217, and was designated pSJ125.

Pe

This sequence was combined with that of pSJ94 to form a consensus sequence "125 + 94", as shown in Figure 10. The sequence of this second gene is about 90% identical at the DNA and protein level to pSJ116, as shown in Figure 5 and 6, and is clearly a second form of SBE II in cassava. The 3' untranslated regions of the two genes are not related (data not shown).

17

It was also determined that the full length cassava SBE II genes (from both leaf and tuber) actually encode for active starch branching enzymes since the cloned genes were able to complement the glycogen branching enzyme deficient *E. coli* mutant KV832.

Main Findings

- 1) A full length cDNA clone of a starch branching enzyme II (SBE II) gene has been cloned from leaves and starch storing roots of cassava. This cDNA encodes a 836 amino acid protein (Mr 95 Kd) and is 86 % identical to pea SBE I over the central conserved domain, although the level of sequence identity over the entire coding region is lower than 86%.
- 2) There is more than one SBE II gene in cassava as a second partial SBE II cDNA was isolated which differs slightly in the protein coding region from the first gene and has no homology in the 3' untranslated region.
- 3) The isolated full length cDNA from both leaves and roots encodes an active SBE as it complements an *E. coli* mutant deficient in glycogen branching enzyme as assayed by iodine staining.

We have shown that there are SBE II (Class A) gene sequences present in the cassava genome by isolating cDNA fragments using 3' and 5' RACE. From these cDNA fragments a consensus sequence of over 3 kb could be compiled which contained one long open reading frame (Figure 2) which is highly homologous to other SBE II (class A) genes (data not shown). It is likely that the consensus sequence does not represent that of a single gene since attempts to PCR a full length gene using primers at the 5' and 3' ends of this sequence were not successful. In fact screening of a number of leaf derived 3'

RACE cDNAs showed that a second SBE II gene (clone designated pSJ101) was also expressed which is highly homologous within the coding region to the originally isolated cDNA (pSJ94) but has a different 3' UTR. A full length SBE II gene was isolated from leaves and roots by PCR using a new primer to the 3' end of this sequence and the original sequence at the 5' end of the consensus sequence. If the frequency of clones isolated by 3' RACE PCR reflects the abundance of the mRNA levels then this full length gene may be expressed at lower levels in the leaf than the pSJ94 clone (2 out of 15 were the former class, 13/15 the latter). It should be noted that each class is expressed in both leaves and roots as judged by PCR (data not shown). Sequence analysis of the predicted ORF of the leaf and root genes showed only a few differences (4 amino acid changes and one deletion) which could have arisen through PCR errors or, alternatively, there may be more than one nearly identical gene expressed in these tissues.

A comparison of all known SBE II protein sequences shows that the cassava SBE II gene is most closely related to the pea gene (Figure 8). The two proteins are 86.3% identical over a 686 amino acid range which extends from the triple proline "elbow" (Burton et al., 1995 Plant J. 7, 3-15) to the conserved VVYA sequence immediately preceding the Cterminal extensions (data not shown). All SBE II proteins are conserved over this range in that they are at least 80% similar to each other. Remarkably however, the sequence conservation between the pea, potato and cassava SBE II proteins also extends to the Nterminal transit peptide, especially the first 12 amino acids of the precursor protein and the region surrounding the mature terminus of the pea protein (AKFSRDS). Because the proteins are so similar around this region it can be predicted that the mature terminus of the cassava SBE II protein is likely to be GKSSHES. The precursor has a predicted molecular mass of 96 kD and the mature protein a predicted molecule mass of 91.3 kD. The cassava SBE II has a short acidic tail at the C-terminal although this is not as long or as acidic as that found in the pea or potato proteins. The significance of this acidic tail, if any, remains to be determined. One notable difference between the amino acid sequence of cassava SBE II and all other SBE II proteins is the presence of the sequence NSKH at around position 697 instead of the conserved sequence DAD/EY. Although this conserved region forms part of a predicted α -helix (number 8) of the catalytic $(\beta/\alpha)_8$ barrel domain (Burton et al 1995 cited previously), this difference does not abolish the SBE activity of the cassava protein as this gene can still complement the glycogen branching deletion mutant of *E. coli*. It may however affect the specificity of the protein. An interesting point is that the other cassava SBE II clone pSJ94 has the conserved sequence DADY.

One other point of interest concerning the sequence of the SBE II gene is the presence of an upstream ATG in the 5' UTR. This ATG could initiate a small peptide of 42 amino acids which would terminate downstream of the predicted initiating methionine codon of the SBE II precursor. If this does occur then the translation of the SBE II protein from this mRNA is likely to be inefficient as ribosomes normally initiate at the 5' most ATG in the mRNA. However the first ATG is in a poorer Kozak context than the SBE II initiator and it may be too close to the 5' end of the message to initiate efficiently (14 nucleotides) thus allowing initiation to occur at the correct ATG.

In conclusion we have shown that cassava does have SBE II gene sequences, that they are expressed in both leaves and tubers and that more than one gene exists.

Example 2 Cloning of a second full length cassava SBE II gene

Methods

Oligonucleotides

| CSBE219 | CTTTATCTATTAAAGACTTC | (Seq ID No. 20) |
|---------|----------------------|-----------------|
| CSBE220 | CAAAAAGTTTGTGACATGG | (Seq ID No. 21) |
| CSBE221 | TCACTTTTTCCAATGCTAAT | (Seq ID No. 22) |
| CSBE222 | TCTCATGCAATGGAACCGAC | (Seq ID No. 23) |
| CSBE223 | CAGATGTCCTGACTCGGAAT | (Seq ID No. 24) |
| CSBE224 | ATTCCGAGTCAGGACATCTG | (Seq ID No. 25) |
| CSBE225 | CGCATTTCTCGCTATTGCTT | (Seq ID No. 26) |
| CSBE226 | CACAGGCCCAAGTGAAGAAT | (Seq ID No. 27) |

The 5' end of the gene corresponding to the 3'RACE clone pSJ94 was isolated in three

rounds of 5'RACE. Prior to performing the first round of 5' RACE, 5 μ g of total leaf RNA was reverse transcribed in a 20 μ l reaction using conditions as decribed by the manufacturer (Superscript enzyme, BRL) and 10 pmol of the SBE II gene specific primer CSBE23. Primers were then removed and the cDNA tailed with dATP as described above. The first round of 5'RACE used primers CSBE216 and Ro. This PCR reaction was diluted 1:20 and used as a template for a second round of amplification using primers CSBE217 and Ri. The gene specific primers were designed so that they would preferentially hybridise to the SBE II sequence in pSJ94. Amplified products appeared as a smear of approximately 600-1200 bp when subjected to electrophoresis on a 1% TAE agarose gel.

This smear was excised and DNA purified using a Qiaquick column (Qiagen) before ligation to the pT7Blue vector. Several clones were sequenced and clone #7 was designated pSJ125. New primers (CSBE219 and 220) were designed to hybridise to the 5' end of pSJ125 and a second round of 5'RACE was performed using the same CSBE23 primed library. Two fragments of 600 and 800 bp were cloned and sequenced (clones 13,17). Primers CSBE221 and 222 were designed to hybridise to the 5' sequence of the longest clone (#13) and a third round of 5' RACE was performed on a new library (5 µg total leaf RNA reverse transcribed with Superscript using CSBE220 as primer and then dATP tailed with TdT from Boehringer Mannheim). Fragments of approximately 500 bp were amplified, cloned and sequenced. Clone #13, was designated pSJ143. The process is illustrated schematically in Figure 12.

To isolate a full length gene as a contiguous sequence, a new primer (CSBE225) was designed to hybridise to the 5' end of clone pSJ143 and used with one of the primers (CSBE226 or 23) in the 3' end of clone pSJ94, in a PCR reaction using RoRidT17 primed leaf cDNA as template. Use of primer CSBE226 resulted in production of Clone #2 (designated pSJ144), and use of primer CSBE23 resulted in production of Clones #10 and 13 (designated pSJ145 and pSJ146 respectively). Only pSJ146 was sequenced fully.

Results

Isolation of a second full length cassava SBE II gene

A full length clone for a second SBE II gene was isolated by extending the sequence of pSJ94 in three rounds of 5' RACE as illustrated schematically in Figure 12. In each round of 5' RACE, primers were designed that would preferentially hybridise to the new sequence rather than to the gene represented by pSJ116. In the final round of 5' RACE, three clones were obtained that had the initiating methione codon, and none of these had upstream ATGs. The overlapping cDNA fragments (sequences of the 5'RACE clones pSJ143, 13, pSJ125 and the 3'RACE clone pSJ94) could be assembled into a consensus sequence of approximately 3 kb which was designated csbe2-2.seq. This sequence contained one long ORF with a predicted size of 848 aa (M_r 97 kDa). The full length gene was then isolated as a contiguous sequence by PCR amplification from RoRidT17 primed leaf cDNA using primers at the 5' (CSBE225) and 3' (CSBE23 or CSBE226) ends of the RACE clones. One clone, designated pSJ146, was sequenced and the restriction map is shown along with the predicted amino acid sequence in Figure 13.

Sequence homologies between SBE II genes

The two cassava genes (pSJ116 and pSJ146) share 88.8% identity at the DNA level over the entire coding region (data not shown). The homology extends about 50 bases outside of this region but beyond this the untranslated regions show no similarity (data not shown). At the protein level the two genes show 86% identity over the entire ORF (data not shown). The two genes are more closely related to each other than to any other SBE II. Between species, the pea SBE I shows the most homology to the cassava SBE II genes.

Example 3

Construction of plant transformation vectors and transformation of cassava with antisense starch branching enzyme genes.

This example describes in detail how a portion of the SBE II gene isolated from cassava may be introduced into cassava plants to create transgenic plants with altered properties.

An 1100 bp *Hind* III - *Sac* I fragment of cassava SBE II (from plasmid pSJ94) was cloned into the *Hind* III - *Sac* I sites of the plant transformation vector pSJ64 (Figure 11). This placed the SBE II gene in an antisense orientation between the 2X 35S CaMV promoter

and the nopaline synthase polyadenylation signal. pSJ64 is a derivative of the binary vector pGPTV-HYG (Becker et al., 1992 Plant Molecular Biology 20: 1195-1197) modified by inclusion of an approximately 750 bp fragment of pJIT60 (Guerineau et al 1992 Plant Mol. Biol. 18, 815-818) containing the duplicated cauliflower mosaic virus (CaMV) 35S promoter (Cabb-JI strain, equivalent to nucleotides 7040 to 7376 duplicated upstream of 7040 to 7433, as described by Frank et al., 1980 Cell 21, 285-294) to replace the GUS coding sequence. A similar construct was made with the cassava SBE II sequence from plasmid pSJ101.

These plasmids are then introduced into Agrobacterium tumefaciens LBA4404 by a direct DNA uptake method (An et al., Binary vectors, In: Plant Molecular Biology Manual (ed Galvin and Schilperoort) AD 1988 pp 1-19) and can be used to transform cassava somatic embryos by selecting on hygromycin as described by Li et al. (1996, Nature Biotechnology 14, 736-740).

SEQUENCE LISTING

| (1) GENERAL INFORMATION: | |
|---|----|
| (i) APPLICANT: (A) NAME: National Starch and Chemical Investment | |
| (ii) TITLE OF INVENTION: Improvements in or Relating to Starch Content of Plants | |
| (iii) NUMBER OF SEQUENCES: 31 | |
| <pre>(iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0. Version #1.30 (EPO)</pre> | |
| (2) INFORMATION FOR SEQ ID NO: 1: | |
| (i) SEQUENCE CHARACTERISTICS:(A) LENGTH. 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | |
| (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: | |
| ATGGACAAGG ATATGTATGA | 20 |
| (2) INFORMATION FOR SEQ ID NO: 2: | |
| (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: | |
| GGTTTCATGA CTTCTGAGCA | 20 |
| (2) INFORMATION FOR SEO ID NO: 3: | |

(i) SEQUENCE CHARACTERISTICS:

| | (A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | |
|------|--|----|
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: | |
| TGCT | CAGAAG TCATGAAACC | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 4: | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: | |
| TCCA | AGTCTCA ATATACGTCG | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 5: | |
| (2) | | |
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: | |
| AGGA | AGTAGAT GGTCTGTCGA | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 6: | |
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | - |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: | • |
| TCAT | TACATAT CCTTGTCCAT | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 7: | |
| (2) | | |
| - | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |

| (xi | i) SEQUENCE DESCRIPTION: SEQ ID NO: 7: | |
|---------|---|----|
| GGGTGAC | CTTC AATGATGTAC | 20 |
| (2) INF | FORMATION FOR SEQ ID NO: 8: | |
| | i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| (x- | i) SEQUENCE DESCRIPTION: SEQ ID NO: 8: | |
| GGTGTA | CATC ATTGAAGTCA | 20 |
| (2) IN | FORMATION FOR SEQ ID NO: 9: | |
| | i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| (x | (i) SEQUENCE DESCRIPTION: SEQ ID NO: 9: | |
| AATTAC | TTGGC TCCGTACTAC | 20 |
| (2) IN | IFORMATION FOR SEQ ID NO: 10: | |
| • • | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| (x | (i) SEQUENCE DESCRIPTION: SEQ ID NO: 10: | |
| • | CAACG TGCGACTCAT | 20 |
| (2) IN | NFORMATION FOR SEQ ID NO: 11: | |
| , _ , | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| (: | xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: | |
| TACCG | GTAAT CTAGGTGTTG | 20 |

| (2) | INFORMATION FOR SEQ ID NO: 12: | |
|-------|--|----|
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: | |
| GGAC | CCTTGGT TTAGATCCAA | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 13: | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: | |
| ATG/ | AGTCGCA CGTTGGAATG | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 14: | |
| (2) | | |
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: | |
| CAA | CACCTAG ATTACCGGTA | 20 |
| (2) | INCORMATION COR CEO ID NO. 15. | |
| (2) | INFORMATION FOR SEQ ID NO: 15: | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: | |
| TTA | GTTGCGT CAGTTCTCAC – | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 16: | |
| . – , | (i) SEQUENCE CHARACTERISTICS: | |
| | (A) LENGTH: 20 base pairs | |

| | 27 | |
|--|------------|----|
| (B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | · | |
| (xi) SEQUENCE DESCRIPTION: SEQ | ID NO: 16: | |
| AATATCTATC TCAGCCGGAG | | 20 |
| (2) INFORMATION FOR SEQ ID NO: 17: | | |
| (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | | |
| (xi) SEQUENCE DESCRIPTION: SEQ | ID NO: 17: | |
| ATCTTAGATA GTCTGCATCA | | 20 |
| (2) INFORMATION FOR SEQ ID NO: 18: | | |
| (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | 5 | |
| (xi) SEQUENCE DESCRIPTION: SEQ | ID NO: 18: | |
| TGGTTGTTCC CTGGAATTAC | | 20 |
| (2) INFORMATION FOR SEQ ID NO: 19: | | |
| (i) SEQUENCE CHARACTERISTICS: | 5 | |
| (xi) SEQUENCE DESCRIPTION: SEQ | ID NO: 19: | |
| TGCAAGGACC GTGACATCAA | | 20 |
| (2) INFORMATION FOR SEQ ID NO: 20: | | |
| (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | 5 | |

| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: | |
|------|--|----|
| СТТ | TATCTAT TAAAGACTTC | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 21: | |
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: | |
| CAAA | AAAAGTT TGTGACATGG | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 22: | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: | |
| TCAC | CTTTTTC CAATGCTAAT | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 23: | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: | |
| TCTC | CATGCAA TGGAACCGAC | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 24: | |
| (2) | (i) SEQUENCE CHARACTERISTICS: | |
| | (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | |
| | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: | |
| CAGA | ATGTCCT GACTCGGAAT | 20 |

| | | 23 | • | | | | | | | |
|------|--|-------|-----------------|------------|------------|------------|------------|------------------|---|----|
| (2) | INFORMATION FOR SEQ ID NO: 25: | | | | | | | | | |
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | | | | | | | | - | |
| | (xi) SEQUENCE DESCRIPTION: SEQ | ID N | 0: 2 | 25 : | | | | | | |
| ATTO | CCGAGTC AGGACATCTG | | - | | | | | | | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 26: | | | | | | | | | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | ; | | | | | | | | |
| | (xi) SEQUENCE DESCRIPTION: SEQ | ID N | 0: : | 26: | | | | | | |
| CGCA | ATTTCTC GCTATTGCTT | | | | | | | | | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 27: | | | | | | | | | |
| | (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear | 5 | | | | | | | | |
| | (xi) SEQUENCE DESCRIPTION: SEQ | ID N | 10: | 27 : | | | | | | |
| CAC | AGGCCCA AGTGAAGAAT | | | | | • | | | | 20 |
| (2) | INFORMATION FOR SEQ ID NO: 28: | | | | | | | | | |
| , | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2588 base partial (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear | irs | | | - ** | | | - | | |
| | (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:212531 | | | | | | | | | |
| | (xi) SEQUENCE DESCRIPTION: SEQ | ID N | 10: | 28: | | | | | | |
| СТС | TCTAACT TCTCAGCGAA ATG GGA CAC Met Gly His | TAC A | ACC Thr 5 | ATA Ile | TCA Ser | GGA Gly | ATA Ile | CGT Arg 10 | | 50 |

| | | | | | | | | | 50 | | | | | | | | |
|-------------------|-------------------|------------------|-------------------|-------------------|-------------------|------------------|------------------|-------------------|-------------------|-------------------|------------------|------------------|-------------------|-------------------|-------------------|---|-----|
| TTT Phe | CCT Pro | TGT Cys | GCT Ala | CCA Pro 15 | CTC Leu | TGC Cys | AAA Lys | TCT Ser | CAA Gln 20 | TCT Ser | ACC Thr | GGC Gly | TTC Phe | CAT His 25 | GGC Gly | | 98 |
| TAT Tyr | CGG Arg | AGG Arg | ACC Thr 30 | TCC Ser | TCT Ser | TGC Cys | CTT Leu | TCC Ser 35 | TTC Phe | AAC Asn | TTC Phe | AAG Lys | GAG G1u 40 | GCG Ala | TTT Phe | | 146 |
| TCT Ser | AGG Arg | AGG Arg 45 | GTC Val | TTC Phe | TCT Ser | GGA Gly | AAG Lys 50 | TCA Ser | TCT Ser | CAT His | GAA Glu | TCT Ser 55 | GAC Asp | TCC Ser | TCA Ser | | 194 |
| AAT Asn | GTA Val 60 | ATG Met | GTC Val | ACT Thr | GCT Ala | TCT Ser 65 | AAA Lys | AGA Arg | GTC Val | CTT Leu | CCT Pro 70 | GAT Asp | GGT Gly | CGG Arg | ATT Ile | | 242 |
| GAA G1u 75 | TGC Cys | TAT Tyr | TCT Ser | TCT Ser | TCA Ser 80 | ACA Thr | GAT Asp | CAA Gln | TTG Leu | GAA Glu 85 | GCC Ala | CCT Pro | GGC Gly | ACA Thr | GTT Val 90 | | 290 |
| | GAA Glu | | | | | | | | | | | | | | | | 338 |
| GAT Asp | AAG Lys | ATT Ile | GTT Val 110 | GAA Glu | GAT Asp | GAA Glu | GTA Val | AAT Asn 115 | AAA Lys | GAA Glu | TCT Ser | GTT Val | CCA Pro 120 | ATG Met | CGG Arg | | 386 |
| | ACA Thr | | | | | | | | | | | | | | | | 434 |
| | CCC Pro 140 | | | | | | | | | | | | | | | | 482 |
| GGC Gly 155 | TTT Phe | CGT Arg | CAA Gln | CAC His | CTA Leu 160 | GAT Asp | TAC Tyr | CGG Arg | TAT Tyr | TCA Ser 165 | CAG Gln | TAC Tyr | AAA Lys | AGA Arg | CTC Leu 170 | | 530 |
| CGA Arg | GAA Glu | GAA G1u | ATT Iìe | GAC Asp 175 | AAG Lys | TAT Tyr | GAA Glu | GGT Gly | AGT Ser 180 | CTG Leu | GAT Asp | GCA Ala | TTT Phe | TCT Ser 185 | CGT Arg | | 578 |
| | TAT Tyr | | | | | | | | | | | | | | | - | 626 |
| | GAG Glu | | | | | | | | | | | | | | | | 674 |
| | AAC Asn 220 | | | | | | | | | | | | | | | | 722 |

| | | | | | | | | | - | | | | | | | | |
|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|-------------|
| GTC Val 235 | TGG Trp | GAG Glu | ATC Ile | TTT Phe | TTG Leu 240 | CCG Pro | AAT Asn | AAT Asn | GCA Ala | GAT Asp 245 | GGT Gly | TCA Ser | CCA Pro | CCA Pro | ATT Ile 250 | • | 770 |
| CCC Pro | CAT His | GGT Gly | TCT Ser | CGA Arg 255 | GTA Val | AAG Lys | ATA Ile | CGC Arg | ATG Met 260 | GAT Asp | ACT Thr | CCA Pro | TCT Ser | GGC Gly 265 | AAC Asn | - { | <u>81</u> 8 |
| AAA Lys | GAT Asp | TCT Ser | ATT Ile 270 | CCT Pro | GCT Ala | TGG Trp | ATC- Ile | AAG Lys 275 | TTC Phe | TCA Ser | GTT Val | CAA Gln | GCA Ala 280 | CCA Pro | GGT Gly | { | 866 |
| GAA Glu | CTC Leu | CCA Pro 285 | TAT Tyr | AAT Asn | GGC Gly | ATA Ile | TAC Tyr 290 | TAT Tyr | GAT Asp | CCT Pro | CCC Pro | GAG G1u 295 | GAG Glu | GAG Glu | AAG Lys | 9 | 914 |
| TAT Tyr | GTG Val 300 | TTC Phe | AAA Lys | AAT Asn | CCT Pro | CAG G1n 305 | CCA Pro | AAG Lys | AGA Arg | CCA Pro | AAA Lys 310 | TCA Ser | CTT Leu | CGG Arg | ATT Ile | į | 962 |
| TAT Tyr 315 | GAG Glu | TCG Ser | CAC His | GTT Val | GGA Gly 320 | ATG Met | AGT Ser | AGT Ser | ACG Thr | GAG G1u 325 | CCA Pro | GTA Val | ATT Ile | AAC Asn | ACA Thr 330 | 10 | 010 |
| TAT Tyr | GCC Ala | AAC Asn | TTT Phe | AGA Arg 335 | GAT Asp | GAT Asp | GTG Val | CTT Leu | CCT Pro 340 | CGC Arg | ATC Ile | AAA Lys | AAG Lys | CTT Leu 345 | GGC Gly | 10 | 058 |
| TAC Tyr | AAT Asn | GCT Ala | GTT Val 350 | CAG Gln | CTC Leu | ATG Met | GCT Ala | ATT Ile 355 | CAA Gln | GAG Glu | CAT His | TCA Ser | TAT Tyr 360 | TAT Tyr | GCT Ala | 1 | 106 |
| AGT Ser | TTT Phe | GGG Gly 365 | TAT Tyr | CAC His | GTC· Val | ACA Thr | AAC Asn 370 | TTT Phe | TAT Tyr | GCA Ala | GCT Ala | AGC Ser 375 | AGC Ser | CGA Arg | TTT Phe | . 13 | 154 |
| GGA Gly | ACT Thr 380 | CCT Pro | GAT Asp | GAT Asp | TTA Leu | AAG Lys 385 | TCT Ser | CTA Leu | ATA Ile | GAT Asp | AAA Lys 390 | GCT Ala | CAC His | GAG Glu | TTA Leu | 12 | 202 |
| | CTT Leu | | | | | | | | | | | | | | | 1: | 250 |
| | TTG Leu | | | | | | | | | | | | | | | 1 | 298 |
| | TCT Ser | | | | | | | | | | | | | | | 1: | 346 |
| | TAT Tyr | | | | | | | | | | | | | | | 1 | 394 |

• , , •

| | | | | | | | | | 32 | | | | | | • | • | |
|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------------------|-------------------|-------------------|-------------------|-------------------|------|---|
| TGG Trp | TGG Trp 460 | TTG Leu | GAT Asp | GAG G1u | TAC Tyr | AAG Lys 465 | TTT Phe | GAT Asp | GGG Gly | TTC Phe | AGA Arg 470 | TTT Phe | GAT Asp | GGG Gly | GTG Val | 1442 | ? |
| ACT Thr 475 | TCA Ser | ATG Met | ATG Met | TAC Tyr | ACC Thr 480 | CAT His | CAT His | GGA Gly | TTG Leu | CAG Gln 485 | GTA Val | GAT Asp | TTT Phe | ACC Thr | GGC Gly 490 | 1490 |) |
| AAC Asn | TAC Tyr | AAT Asn | GAA Glu | TAC Tyr 495 | TTT Phe | GGA Gly | TAT Tyr | GCA Ala | ACT Thr 500 | GAT Asp | GTA Va 1 | GAT Asp | GCT Ala | GTG Val 505 | GTT Val | 1538 | } |
| TAT Tyr | TTG Leu | ATG Met | CTG Leu 510 | TTG Leu | AAT Asn | GAT Asp | ATG Met | ATT Ile 515 | CAT His | GGT Gly | CTC Leu | TTC Phe | CCA Pro 520 | GAG Glu | GCT Ala | 1586 | ; |
| GTC Val | ACC Thr | ATT Ile 525 | GGT Gly | GAA Glu | GAT Asp | GTT Val | AGT Ser 530 | GGA Gly | ATG Met | CCA Pro | ACA Thr | GTT Val 535 | TGC Cys | ATT Ile | CCG Pro | 1634 | |
| GTT Val | GAA G1u 540 | GAT Asp | GGT Gly | GGT Gly | GTT Val | GGC Gly 545 | TTT Phe | GAT Asp | TAT Tyr | CGT Arg | CT C Leu 550 | CAC His | ATG Met | GCT Ala | GTT Val | 1682 | |
| GCT A1a 555 | GAT Asp | AAA Lys | TGG Trp | Val | GAG G1u 560 | ATT Ile | ATT Ile | CAG Gln | AAG Lys | AGA Arg 565 | GAT Asp | GAA Glu | GAT Asp | TGG Trp | AAA Lys 570 | 1730 | |
| ATG Met | GGT Gly | GAC Asp | ATT Ile | GTA Val 575 | CAT His | ATG Met | CTG Leu | ACC Thr | AAC Asn 580 | AGG Arg | CGG Arg | TGG Trp | TTG Leu | GAA G1u 585 | AAG Lys | 1778 | |
| TGT Cys | GTT Val | -TCT Ser | TAT Tyr 590 | GCT Ala | GAA Glu | AGT Ser | CAT His | GAC Asp 595 | CAG G1n | GCC Ala | CTT Leu | GTT Val | GGT Gly 600 | GAC Asp | AAA Lys | 1826 | |
| ACT Thr | ATT Ile | GCA Ala 605 | TTT Phe | TGG Trp | CTG Leu | ATG Met | GAC Asp 610 | AAG Lys | GAT Asp | ATG Met | TAT Tyr | GAC Asp 615 | TTC Phe | ATG Met | GCT Ala | 1874 | |
| CTT Leu | GAC Asp 620 | AGA Arg | CCA Pro | TCT Ser | ACT Thr | CCT Pro 625 | CTC Leu | ATA Ile | GAT Asp | CGT Arg | GGA Gly 630 | GTA Val | GCA Ala | TTG Leu | CAC His | 1922 | |
| AAA Lys 635 | ATG Met | ATC Ile | AGG Arg | CTT Leu | ATT Ile 640 | ACC Thr | ATG Met | GGA Gly | TTA Leu | GGC Gly 645 | GGA Gly | GAA Glu | GGA Gly | TAT Tyr | TTG Leu 650 | 1970 | |
| AAT Asn | TTT Phe | ATG Met | GGA Gly | AAT Asn 655 | GAA Glu | TTT Phe | GGA Gly | CAC His | CCC Pro 660 | GAG Glu | TGG Trp | ATT Ile | GAT Asp | TTT Phe 665 | CCA Pro | 2018 | |
| AGA Arg | GGT Gly | GAT Asp | CTA Leu 670 | CAT His | CTT Leu | CCC Pro | AGT Ser | GGT Gly 675 | AAA Lys | TTT Phe | GTT Val | CCT Pro | GGG Gly 680 | AAC Asn | AAT Asn | 2066 | |
| | | | | | | | | | | | | | | | | | |

| TAC Tyr | AGT Ser | TAT Tyr 685 | GAT Asp | AAA Lys | TGC Cys | CGG Arg | CGT Arg 690 | AGG Arg | TTT Phe | GAT Asp | CTA Leu | GGC Gly 695 | AAT Asn | TCA Ser | AAG Lys | 2114 |
|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|
| CAT His | CTG Leu 700 | AGA Arg | TAT Tyr | CAT His | GGA Gly | ATG Met 705 | CAA Gln | GAG Glu | TTT Phe | GAT Asp | CAA Gln 710 | GCA Ala | ATT | CAG Gln | CAT His | 2162 |
| CTT Leu 715 | GAA Glu | GAA Glu | GCC Ala | TAT Tyr | GGT Gly 720 | TTC Phe | ATG Met | ACT Thr | TCT Ser | GAG G1u 725 | CAC His | CAA Gln | TAC Tyr | ATA Ile | TCA Ser 730 | 2210 |
| CGG Arg | AAG Lys | GAT Asp | GAA Glu | AGG Arg 735 | GAT Asp | CGG Arg | ATC Ile | ATT Ile | GTC Val 740 | TTC Phe | GAG Glu | AGG Arg | GGA Gly | AAC Asn 745 | ETC Leu | 2258 |
| GTT Val | TTT Phe | GTA Val | TTC Phe 750 | AAT Asn | TTT Phe | CAT His | TGG Trp | ACT Thr 755 | AGC Ser | AGC Ser | TAT Tyr | TCG Ser | GAT Asp 760 | TAC Tyr | CGA Arg | 2306 |
| GTT Val | GGC Gly | TGC Cys 765 | TTA Leu | AAG Lys | CCA Pro | GGA Gly | AAG Lys 770 | TAC Tyr | AAG Lys | ATA Ile | GTC Val | TTG Leu 775 | GAT Asp | TCA Ser | GAT Asp | 2354 |
| GAT Asp | CCT Pro 780 | TTG Leu | TTT Phe | GGA Gly | GGC Gly | TTT Phe 785 | GGC Gly | AGG Arg | CTT Leu | AGT Ser | CAT His 790 | GAT Asp | GCA Ala | GAG Glu | CAC His | 2402 |
| TTC Phe 795 | AGC Ser | TTT Phe | GAA G1u | GGG Gly | TGG Trp 800 | TAC Tyr | GAT Asp | AAC Asn | CGG Arg | CCT Pro 805 | CGA Arg | TCC Ser | TTC Phe | ATG Met | GTG Val 810 | 2450 |
| TAC Tyr | ACA Thr | CCA Pro | TGT Cys | AGA Arg 815 | ACA Thr | GCA Ala | GTG Val | GTC Val | TAT Tyr 820 | GCT Al-a | TTA Leu | GTG Val | GAG Glu | GAT Asp 825 | GAA Glu | 2498 |
| GTG Val | GAG G1u | AAT Asn | GAA Glu 830 | TTG Leu | GAA Glu | CCT Pro | GTC Val | GCC Ala 835 | GGT Gly | TAA * | GATA | ATAT(| CTT A | VACA/ | ACAGGT | 2551 |
| тсте | SAAGO | CAG (| SAAT(| CCAT | T AI | TGAT | СТТС | CTA | TGTT | - | | | | | | 2588 |

(2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 837 amino acids
 - (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

Met Gly His Tyr Thr Ile Ser Gly Ile Arg Phe Pro Cys Ala Pro Leu $1 \hspace{1cm} 5 \hspace{1cm} . \hspace{1cm} 10 \hspace{1cm} - \hspace{1cm} 15$

Cys Lys Ser Gln Ser Thr Gly Phe His Gly Tyr Arg Arg Thr Ser Ser Cys Leu Ser Phe Asn Phe Lys Glu Ala Phe Ser Arg Arg Val Phe Ser Gly Lys Ser Ser His Glu Ser Asp Ser Ser Asn Val Met Val Thr Ala 50 55 60 Ser Lys Arg Val Leu Pro Asp Gly Arg Ile Glu Cys Tyr Ser Ser Ser 65 70 75 80 Thr Asp Gln Leu Glu Ala Pro Gly Thr Val Ser Glu Glu Ser Gln Val Leu Thr Asp Val Glu Ser Leu Ile Met Asp Asp Lys Ile Val Glu Asp 105 100 Glu Val Asn Lys Glu Ser Val Pro Met Arg Glu Thr Val Ser Ile Arg Lys Ile Gly Ser Lys Pro Arg Ser Ile Pro Pro Pro Gly Arg Gly Gln 130 140 Arg Ile Tyr Asp Ile Asp Pro Ser Leu Thr Gly Phe Arg Gln His Leu Asp Tyr Arg Tyr Ser Gln Tyr Lys Arg Leu Arg Glu Glu Ile Asp Lys
165 170 175 Tyr Glu Gly Ser Leu Asp Ala Phe Ser Arg Gly Tyr Glu Lys Phe Gly 180 Phe Ser Arg Ser Glu Thr Gly Ile Thr Tyr Arg Glu Trp Ala Pro Gly 200 Ala Thr Trp Ala Ala Leu Ile Gly Asp Phe Asn Asn Trp Asn Pro Asn 210 215 220 210 Ala Asp Val Met Thr Gln Asn Glu Cys Gly Val Trp Glu Ile Phe Leu 230 Pro Asn Asn Ala Asp Gly Ser Pro Pro Ile Pro His Gly Ser Arg Val 245 250 255 Lys Ile Arg Met Asp Thr Pro Ser Gly Asn Lys Asp Ser Ile Pro Ala 260 265 270 260 Trp Ile Lys Phe Ser Val Gln Ala Pro Gly Glu Leu Pro Tyr Asn Gly 280 Ile Tyr Tyr Asp Pro Pro Glu Glu Glu Lys Tyr Val Phe Lys Asn Pro 290 295 300 Gln Pro Lys Arg Pro Lys Ser Leu Arg Ile Tyr Glu Ser His Val Gly 310 305

Met Ser Ser Thr Glu Pro Val Ile Asn Thr Tyr Ala Asn Phe Arg Asp 330 Asp Val Leu Pro Arg Ile Lys Lys Leu Gly Tyr Asn Ala Val Gln Leu Met Ala <u>Ile</u> Gln Glu His Ser Tyr Tyr Ala Ser Phe Gly Tyr His Val Thr Asn Phe Tyr Ala Ala Ser Ser Arg Phe Gly Thr Pro Asp Asp Leu Lys Ser Leu Ile Asp Lys Ala His Glu Leu Gly Leu Leu Val Leu Met Asp-Ile Val His Ser His Ala Ser Thr Asn Thr Leu Asp Gly Leu Asn 410 Met Phe Asp Gly Thr Asp Gly His Tyr Phe His Ser Gly Pro Arg Gly His His Trp Met Trp Asp Ser Arg Leu Phe Asn Tyr Gly Ser Trp Glu 435 440 445 Val Leu Arg Phe Leu Leu Ser Asn Ala Arg Trp Trp Leu Asp Glu Tyr Lys Phe Asp Gly Phe Arg Phe Asp Gly Val Thr Ser Met Met Tyr Thr 47Ŏ His His Gly Leu Gln Val Asp Phe Thr Gly Asn Tyr Asn Glu Tyr Phe Gly Tyr Ala Thr Asp Val Asp Ala Val Val Tyr Leu Met Leu Leu Asn Asp Met Ile His Gly Leu Phe Pro Glu Ala Val Thr Ile Gly Glu Asp 515 Val Ser Gly Met Pro Thr Val Cys Ile Pro Val Glu Asp Gly Gly Val Gly Phe Asp Tyr Arg Leu His Met Ala Val Ala Asp Lys Trp Val Glu 560 IIe Ile Gln Lys Arg Asp Glu Asp Trp Lys Met Gly Asp Ile Val His 565 570 575 Met Leu Thr Asn Arg Arg Trp Leu Glu Lys Cys Val Ser Tyr Ala Glu Ser His Asp Gln Ala Leu Val Gly Asp Lys Thr Ile Ala Phe Trp Leu Met Asp Lys Asp Met Tyr Asp Phe Met Ala Leu Asp Arg Pro Ser Thr 615

Pro Leu Ile Asp Arg Gly Val Ala Leu His Lys Met Ile Arg Leu Ile 625 630 635 640

Thr Met Gly Leu Gly Gly Glu Gly Tyr Leu Asn Phe Met Gly Asn Glu 645 650 655

Phe Gly His Pro Glu Trp Ile Asp Phe Pro Arg Gly Asp Leu His Leu 660 665 670

Pro Ser Gly Lys Phe Val Pro Gly Asn Asn Tyr Ser Tyr Asp Lys Cys 675 680 685

Arg Arg Arg Phe Asp Leu Gly Asn Ser Lys His Leu Arg Tyr His Gly 690 700

Met Gln Glu Phe Asp Gln Ala Ile Gln His Leu Glu Glu Ala Tyr Gly 705 710 715 720

Phe Met Thr Ser Glu His Gln Tyr Ile Ser Arg Lys Asp Glu Arg Asp 725 730 735

Arg Ile Ile Val Phe Glu Arg Gly Asn Leu Val Phe Val Phe Asn Phe 740 745 750

His Trp Thr Ser Ser Tyr Ser Asp Tyr Arg Val Gly Cys Leu Lys Pro
755 760 _ 765

Gly Lys Tyr Lys Ile Val Leu Asp Ser Asp Asp Pro Leu Phe Gly Gly 770 780

Phe Gly Arg Leu Ser His Asp Ala Glu His Phe Ser Phe Glu Gly Trp 785 790 795 800

Tyr Asp Asn Arg Pro Arg Ser Phe Met Val Tyr Thr Pro Cys Arg Thr 805 810 815

Ala Val Val Tyr Ala Leu Val Glu Asp Glu Val Glu Asn Glu Leu Glu 820 825 830

Pro Val Ala Gly * 835

(2) INFORMATION FOR SEQ ID NO: 30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2805 base pairs
 - (B) TYPE: nucleic acid(C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 131..2677
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

| | | | | | | | | | | | | | | | • | - | |
|------------|-------|-------|-------|---------------|-------|-------|-------|-----|-------|------|------|-------------------|-------|-------|--------|---|-----|
| AGTG | IAAT7 | TCG A | AGCTO | GGTA | AC CO | CGGGG | SATCO | GA7 | TCGC | CATT | TCT(| CGCTA | ATT (| CTTT | rccgtt | | 60 |
| TATT | TCCA | ATA 1 | TATA/ | V AATA | AT CA | VAAT(| TAAT | CAC | CTTGC | CGCC | ATT | ГСТАТ | ГСТ (| стстс | CCAAAC | | 120 |
| ТСТС | ACCG | | | /al 1 | | | | | Ser (| | | CGT 1 Arg F | | ro (| | | 169 |
| | | | | | | | | | | | | CAT His | | | | | 217 |
| | | | | | | | | | | | | GAG Glu | | | | | 265 |
| | | | | | | | | | | | | GAC Asp 895 | | | | | 313 |
| Leu | | | | | | | | | | | | GAT Asp | | | | • | 361 |
| | | | | | | | | | | | | ACT Thr | | | | | 409 |
| | | | | | | | | | | | | CTT Leu | | | | | 457 |
| | | | | | | | | | | | | GAG Glu | | | | | 505 |
| TTG Leu | | | | | | | | | | | | AAA Lys 975 | | | | | 553 |
| | | | | | | | | | | | | ATA Ile | | | | | 601 |
| | | | | | | His | | | | | Tyr | TCA Ser | | | | | 649 |
| | | | | | Пe | | | | | Gly | | TTG Leu | | | Phe | | 697 |
| | | | | Glu | | | | | Leu | | | GAA Glu | | Gly | | | 745 |

| | | | 30 | | | • | •• |
|------------------------------------|--------------------------------|--|-----------------------------|----------------------------|----------------------------|----------------------------|------|
| ACT TAT AGG Thr Tyr Arg 1045 | Glu Irp A | CA CCT GGA la Pro Gly 105 | ⁄ Ala Thr | TGG GCT Trp Ala | GCA CTT Ala Leu 1055 | ATT GGA Ile Gly | 793 |
| GAT TTC AAC Asp Phe Asn 1060 | AAT TGG A Asn Trp A | AT CCT AA ⁻ sn Pro Asr 1065 | GCA GAT Ala Asp | GTC ATG Val Met 1070 | Thr Arg | AAT GAG Asn Glu | 841 |
| TTT GGT GTC Phe Gly Val 1075 | Trp Glu I | TT TTT TT(le Phe Lei 080 | G CCA AAT I Pro Asn | AAC GCA Asn Ala 1085 | GAT GGT Asp Gly | TCA CCA Ser Pro 1090 | 889 |
| CCA ATT CCT Pro Ile Pro | CAT GGT T His Gly S 1095 | CT CGA GTA er Arg Va | A AAG ATA Lys Ile 110 | Arg Met | GAT ACT Asp Thr | CCA TCT Pro Ser 1105 | 937 |
| GGC ATC AAA Gly Ile Lys | GAT TCA A Asp Ser I 1110 | TT CCT GCT le Pro Ala | TGG ATC Trp Ile 1115 | AAG TTC Lys Phe | TCA GTT Ser Val 1120 | Gln Ala | 985 |
| CCT GGT GAA Pro Gly Glu 1125 | Ile Pro T | AC AAT GCC yr Asn Ala 113 | ı Ile Tyr | TAT GAT Tyr Asp | CCA CCA Pro Pro 1135 | AAG GAG Lys Glu | 1033 |
| GAG AAG TAT Glu Lys Tyr 1140 | GTG TTC A Val Phe L | AA CAT CCT ys His Pro 1145 | CAG CCA Gln Pro | AAG AGA Lys Arg 1150 | Pro Lys | TCA CTT Ser Leu | 1081 |
| AGG ATT TAT Arg Ile Tyr 1155 | Glu Ser H | AT GTT GGO is Val Gly 160 | ATG AGT Met Ser | AGT ATG Ser Met 1165 | GAG CCA Glu Pro | ATA ATT Ile Ile 1170 | 1129 |
| AAC ACA TAT Asn Thr Tyr | | | | Leu Pro | | | 1177 |
| CTT GGC TAC Leu Gly Tyr | | | | | | Ser Tyr | 1225 |
| TAT GCT AGT Tyr Ala Ser 1205 | Phe Gly T | | Thr Asn | | | | 1273 |
| CGA TTT GGA Arg Phe Gly 1220 | | | | | Asp Lys | | 1321 |
| GAG TTA GGG Glu Leu Gly 1235 | Leu Leu V | | | | | | 1369 |
| AAT AAT ACG Asn Asn Thr | | | | Asp Gly | | | 1417 |

| | | | | | | | | | 39 | | | | | | `. | • |
|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|------|
| TAC Tyr | TTC Phe | CAC His | TCC Ser 127 | uly | TCA Ser | CGG Arg | GGT Gly | CAT His 127 | His | TGG Trp | TTG Leu | TGG Trp | GAC Asp 128 | Ser | CGC Arg | 1465 |
| CTT Leu | TTC Phe | AAC Asn 128 | Tyr | GGA Gly | AGC Ser | TGG Trp | GAG Glu 129 | Val | CTA Leu | AGA Arg | TTT Phe | CTT Leu 129 | Leu | TCA Ser | AAT Asn | 1513 |
| GCA Ala | AGA Arg 1300 | 1rp | TGG Trp | TTG Leu | GAA Glu | GAG Glu 130 | Tyr | AGG Arg | TTT Phe | GAT Asp | GGT Gly 131 | Phe | AGA Arg | TTT Phe | GAT Asp | 1561 |
| GGG Gly 131 | Val | ACT Thr | TCC Ser | ATG Met | ATG Met 1320 | Tyr | ACT Thr | CCC Pro | CAT His | GGG Gly 1329 | Leu | CAG Gln | GTA Val | GCT Ala | TTT Phe 1330 | 1609 |
| ACT Thr | GGC Gly | AAC Asn | TAC Tyr | AAT Asn 1335 | Glu | TAC Tyr | TTT Phe | GGA Gly | TAT Tyr 1340 | GCA Ala) | ACT Thr | GAT Asp | GTA Val | GAT Asp 134 | Ala | 1657 |
| GTG Val | ATT Ile | TAT Tyr | TTG Leu 1350 | Met | CTT Leu | GTG Val | AAT Asn | GAT Asp 135 | Met | ATT Ile | CAC His | GGT Gly | CTT Leu 1360 | Phe | CCT Pro | 1705 |
| GAG Glu | GCT Ala | GTT Val 1365 | Thr | ATT Ile | GGT Gly | GAA Glu | GAT Asp 1370 | Val | AGC Ser | GGA Gly | AAG Lys | CCA Pro 1375 | Thr | TTT Phe | TGC Cys | 1753 |
| ATT Ile | CCA Pro 1380 | Val | GAA Glu | GAT Asp | GGT Gly | GGT Gly 1385 | Val | GGA Gly | TTT Phe | GAT Asp | TAC Tyr 1390 | Arg | CTC Leu | CAC His | ATG Met | 1801 |
| GCC Ala 1395 | He | GCC Ala | GAT Asp | AAA Lys | TGG Trp 1400 | He | GAG G1u | ATT Ile | CTT Leu | AAG Lys 1405 | Lys | AGA Arg | GAT Asp | GAG Glu | GAC Asp 1410 | 1849 |
| TGG Trp | AAA Lys | ATG Met | GGT Gly | GAC Asp 1415 | He | GTG Val | CAT His | ACA Thr | CTC Leu 1420 | ACC Thr | AAC Asn | AGA Arg | AGG Arg | TGG Trp 1425 | Leu | 1897 |
| GAA G1u | AAA Lys | TGT Cys | GTT Val 1430 | Ala | TAT Tyr | GCT Ala | GAA G1u | AGT Ser 1435 | His | GAC Asp | CAA Gln | GCT Ala | CTT Leu 1440 | Va 1 | GGT Gly | 1945 |
| GAC Asp | AAA Lys | ACT Thr 1445 | He | GCA Ala | TTT Phe | Trp | CTG Leu 1450 | Met | GAC Asp | AAG Lys | GAC Asp | ATG Met 1455 | Tyr | GAC Asp | TTC Phe | 1993 |
| ATG Met | GCT Ala 1460 | Arg | GAC Asp | AGA Arg | CCA Pro | TCT Ser 1465 | Thr | CCT Pro | CTT Leu | ATA Ile | GAT Asp 1470 | Arg | GGA Gly | ATA Ile | GCA Ala | 2041 |
| TTG Leu 1475 | HIS | AAA Lys | ATG Met | ATC Ile | AGG Arg 1480 | Leu | ATT | ACC Thr | ATG Met | GGC Gly 1485 | Leu | GGC Gly | GGA Gly | GAA Glu | GGA Gly 1490 | 2089 |
| | | | | | | | | | | | | | | | | |

| | | | | | | | | | 40 | | | | | | | - |
|---|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------|
| TAT Tyr | TTG Leu | AAT Asn | TTT Phe | ATG Met 149 | ыy | AAT Asn | GAA G1u | TTT Phe | GGA Gly 150 | His | CCT Pro | GAG G1u | TGG Trp | ATT Ile 150 | GAT Asp 5 | 2137 |
| TTT Phe | CCA Pro | AGA Arg | GGG Gly 1510 | Asp | CGA Arg | CAT His | CTG Leu | CCC Pro 151 | Asn | GGT Gly | AAA Lys | GTA Val | ATT Ile 152 | Pro | GGG Gly | 2185 |
| AAC . Asn . | AAC Asn | CAC His 1525 | Ser | TAT Tyr | GAT Asp | AAA Lys | TGC Cys 1530 | Arg | CGT Arg | AGA Arg | TTT Phe | GAT Asp 153 | Leu | GGT Gly | GAT Asp | 2233 |
| GCA (| GAC Asp 1540 | Tyr | CTA Leu | AGA Arg | TAT Tyr | CAT His 1549 | Gly | ATG Met | CAA Gln | GAG Glu | TTT Phe 155(| Asp | CAG Gln | GCA Ala | ATG Met | 2281 |
| CAA (Gln I 1555 | HIS | CTT Leu | GAA G1u | GAA Glu | GCC Ala 1560 | Tyr | GGT Gly | TTC Phe | ATG Met | ACT Thr 1565 | Ser | GAG G1u | CAC His | CAG Gln | TAT Tyr 1570 | 2329 |
| ATA T | TCA Ser | CGG Arg | AAG Lys | GAT Asp 1575 | Glu | GGA Gly | GAT Asp | CGG Arg | ATC Ile 1580 | Ile | GTC Val | TTT Phe | GAG Glu | AGG Arg 1589 | Gly | 2377 |
| AAC (Asn l | CTT Leu | GTT Val | TTT Phe 1590 | Val | TTC Phe | AAC Asn | TTT Phe | CAT His 1595 | Trp | ACT Thr | AAC Asn | AGC Ser | TAT Tyr 1600 | Ser | GAT Asp | 2425 |
| TAC (| CGA Arg | GTT Val 1605 | Gly | TGC Cys | TTC Phe | AAG Lys | TCA Ser 1610 | Gly | AAG Lys | TAC Tyr | AAG Lys | ATT Ile 1615 | Val | TTG Leu | GAC Asp | 2473 |
| TCG (Ser / | GAT Asp 1620 | Asp | GGC Gly | TTG Leu | TTT Phe | GGA Gly 1625 | Gly | TTC Phe | AAC Asn | AGG Arg | CTT Leu 1630 | Ser | CAT His | GAT Asp | GCC Ala | 2521 |
| GAG (Glu H 1635 | CAC His | TTC Phe | ACC Thr | Phe | GAC Asp 1640 | Gly | TGG Trp | TAT Tyr | GAT Asp | AAC Asn 1645 | Arg | CCT Pro | CGG Arg | TCC Ser | TTC Phe 1650 | 2569 |
| ATG 6 | GTA Val | TAT Tyr | Ala | CCA Pro 1655 | Ser | AGG Arg | ACA Thr | GCA Ala | GTG Val 1660 | Val | TAT Tyr | GCT Ala | TTA Leu | GTA Val 1665 | Glu | 2617 |
| GAT G Asp G | GAA Glu | Glu | AAT Asn 1670 | Glu | GCA Ala | GAG G1u | AAT Asn | GAA Glu 1675 | Va1 | GAA Glu | AGT Ser | GAA Glu | GTG Val 1680 | Lys | CCA Pro | 2665 |
| GCC T Ala S | ser | GGC Gly 1685 | * | GATA | GATA | TT T | AGTA | AGAG | ig at | CCCC | TAAA | GCA | .GGAA | TGG | | 2717 |
| TTAACCTGTG CATCTGCATT GAACGACGTA TATTGAGACT GGAAATCCAT ATGACTAGTA 277 | | | | | | | | | | | | 2777 | | | | |
| GATCC | СТСТ | AG A | GTCG | ACCT | G CA | GGCA | TG | | | | | | | - | | - 2805 |
| | | | | | | | | | | | | | | | | |

(2) INFORMATION FOR SEQ ID NO: 31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 849 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Met Val Tyr Tyr Thr Val Ser Gly Ile Arg Phe Pro Cys Ala Pro Ser 1 5 10 15

Leu Tyr Lys Ser Gln Leu Thr Ser Phe His Gly Gly Arg Arg Thr Ser 20 25 30

Ser Gly Leu Ser Phe Leu Leu Lys Lys Glu Leu Phe Pro Arg Lys Ile 35 40 45

Phe Ala Gly Lys Ser Ser Tyr Glu Ser Asp Ser Ser Asn Leu Thr Val
50 60

Ser Ala Ser Glu Lys Val Leu Val Pro Asp Asp Gln Ile Asp Gly Ser 65 70 75 80

Ser Ser Ser Thr Tyr Gln Leu Glu Thr Thr Gly Thr Val Leu Glu Glu 85 90 95

Ser Gln Val Leu Gly Asp Ala Glu Ser Leu Val Met Glu Asp Asp Lys

Asn Val Glu Glu Asp Glu Val Lys Lys Glu Ser Val Pro Leu His Glu 115 120 125

Thr Ile Ser Ile Gly Lys Ser Glu Ser Lys Pro Arg Ser Ile Pro Pro 130 135 140

Pro Gly Ser Gly Gln Arg Ile Tyr Asp Ile Asp Pro Ser Leu Ala Gly 145 150 155 160

Phe Arg Gln His Leu Asp Tyr Arg Tyr Ser Gln Tyr Lys Arg Leu Arg 165 170 175

Glu Glu Ile Asp Lys Tyr Glu Gly Gly Leu Asp Ala Phe Ser Arg Gly 180 185 190

Phe Glu Lys Phe Gly Phe Leu Arg Ser Glu Thr Gly Ile Thr Tyr Arg 195 200 205

Glu Trp Ala Pro Gly Ala Thr Trp Ala Ala Leu Ile Gly Asp Phe Asn 210 215 220

Asn Trp Asn Pro Asn Ala Asp Val Met Thr Arg Asn Glu Phe Gly Val 225 235 240

Trp Glu Ile Phe Leu Pro Asn Asn Ala Asp Gly Ser Pro Pro Ile Pro His Gly Ser Arg Val Lys Ile Arg Met Asp Thr Pro Ser Gly Ile Lys 265 270 Asp Ser Ile Pro Ala Trp Ile Lys Phe Ser Val Gln Ala Pro Gly Glu 275 280 285 Ile Pro Tyr Asn Ala Ile Tyr Tyr Asp Pro Pro Lys Glu Glu Lys Tyr 290 295 300 Val Phe Lys His Pro Gln Pro Lys Arg Pro Lys Ser Leu Arg Ile Tyr 305 310 315 320 Glu Ser His Val Gly Met Ser Ser Met Glu Pro Ile Ile Asn Thr Tyr 325 330 335 Ala Asn Phe Arg Asp Asp Met Leu Pro Arg Ile Lys Lys Leu Gly Tyr Asn Ala Val Gln Ile Met Ala Ile Gln Glu His Ser Tyr Tyr Ala Ser 355 360 365 Phe Gly Tyr His Val Thr Asn Phe Phe Ala Pro Ser Ser Arg Phe Gly 375 Thr Pro Asp Asp Leu Lys Ser Leu Ile Asp Lys Ala His Glu Leu Gly Leu Leu Val Leu Met Asp Ile Val His Ser His Ala Ser Asn Asn Thr 405 Leu Asp Gly Leu Asn Met Phe Asp Gly Thr Asp Ser His Tyr Phe His 420 425 430 Ser Gly Ser Arg Gly His His Trp Leu Trp Asp Ser Arg Leu Phe Asn 440 Tyr Gly Ser Trp Glu Val Leu Arg Phe Leu Leu Ser Asn Ala Arg Trp Trp Leu Glu Glu Tyr Arg Phe Asp Gly Phe Arg Phe Asp Gly Val Thr 475 470 480 Ser Met Met Tyr Thr Pro His Gly Leu Gln Val Ala Phe Thr Gly Asn Tyr Asn Glu Tyr Phe Gly Tyr Ala Thr Asp Val Asp Ala Val Ile Tyr 500 505 Leu Met Leu Val Asn Asp Met Ile His Gly Leu Phe Pro Glu Ala Val 520 Thr Ile Gly Glu Asp Val Ser Gly Lys Pro Thr Phe Cys Ile Pro Val 530 540

SUBSTITUTE SHEET (RULE 26)



Glu Asp Gly Gly Val Gly Phe Asp Tyr Arg Leu His Met Ala Ile Ala Asp Lys Trp Ile Glu Ile Leu Lys Lys Arg Asp Glu Asp Trp Lys Met 565 570 575 Gly Asp Ile Val His Thr Leu Thr Asn Arg Arg Trp Leu Glu Lys Cys Val Ala Tyr Ala Glu Ser His Asp Gln Ala Leu Val Gly Asp Lys Thr 595 600 605 Ile Ala Phe Trp Leu Met Asp Lys Asp Met Tyr Asp Phe Met Ala Arg 610 620 Asp Arg Pro Ser Thr Pro Leu Ile Asp Arg Gly Ile Ala Leu His Lys 625 630 635 640 Met Ile Arg Leu Ile Thr Met Gly Leu Gly Gly Glu Gly Tyr Leu Asn 645 650 655 Phe Met Gly Asn Glu Phe Gly His Pro Glu Trp Ile Asp Phe Pro Arg Gly Asp Arg His Leu Pro Asn Gly Lys Val Ile Pro Gly Asn Asn His 675 680 685 Ser Tyr Asp Lys Cys Arg Arg Arg Phe Asp Leu Gly Asp Ala Asp Tyr 690 700 Leu Arg Tyr His Gly Met Gln Glu Phe Asp Gln Ala Met Gln His Leu 705 710 715 720 Glu Glu Ala Tyr Gly Phe Met Thr Ser Glu His Gln Tyr Ile Ser Arg 725 730 735 Lys Asp Glu Gly Asp Arg Ile Ile Val Phe Glu Arg Gly Asn Leu Val 740 745 750 Phe Val Phe Asn Phe His Trp Thr Asn Ser Tyr Ser Asp Tyr Arg Val. 765 Gly Cys Phe Lys Ser Gly Lys Tyr Lys Ile Val Leu Asp Ser Asp Asp 770 780 --Gly Leu Phe Gly Gly Phe Asn Arg Leu Ser His Asp Ala Glu His Phe 785 790 795 800 Thr Phe Asp Gly Trp Tyr Asp Asn Arg Pro Arg Ser Phe Met Val Tyr 805 810 815 Ala Pro Ser Arg Thr Ala Val Val Tyr Ala Leu Val Glu Asp Glu Glu 820 825 830 Asn Glu Ala Glu Asn Glu Val Glu Ser Glu Val Lys Pro Ala Ser Gly